Blogs | MedChemExpress

Navitoclax (ABT-263) is an Orally Active Bcl-2 Inhibitor for Chronic Lymphocytic Leukemia Research

Navitoclax is an orally active Bcl-2 inhibitor targeting to Bcl-xL, Bcl-2, Bcl-w, with anti-tumor activity in vitro and in vivo.
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody

Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
Tiragolumab is An Immune Checkpoint Inhibitor Binding to T-cell Immunoglobulin and TIGIT

Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
Pulrodemstat is a Potent, Selective, Reversible and Orally Active Inhibitor of LSD1

Pulrodemstat is a potent, selective, reversible and orally active LSD1 inhibitor, with anticancer effects.
Ganetespib (STA-9090) is a HSP90 Inhibitor

Ganetespib is a unique Hsp90 inhibitor that exhibits potent and sustained antitumor effects in a broad range of malignancies.
CC-90011 is a Selective and Orally Active Inhibitor of LSD1

CC-90011 is a potent, selective, reversible and orally active LSD1 inhibitor that induces AML and SCLC cells differentiation.
Trilaciclib is an Orally Active CDK4 and CDK6 Inhibitor

Trilaciclib is a CDK4/6 inhibitor with IC50s of 1 nM/4 nM for CDK4/6, respectively. Use for chemotherapy-induced myelosuppression in vivo.
MCP110 is an Inhibitor of Ras/Raf-1 Interaction

MCP110 is an inhibitor of Ras/Raf-1 interaction in human cancer cells. The Ras family GTPases play a central role in the growth factor signaling.
JNJ-64619178 is a Selective PRMT5 Inhibitor with Potent Activity In Lung Cancer

JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (9)